- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Entasis Therapeutics Inc.
Headquarters: Waltham, MA, United States
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Sep 18, 2024
Management Tracks
New CEOs at Nura, IMU
Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | May 16, 2024
Management Tracks
New CMO, CSO at Lantheus
Plus: Barbara Handelin named co-CEO of Transformative Biotech, and updates from Zephyr AI, Venatorx, Glen Clova and more
BioCentury | Jul 25, 2023
Management Tracks
Kevin Oliver named CBO at Acadia
Plus: Editas hires Linda Burkly as CSO, and updates from Bicara, Senda, Aurobac and Velia
BioCentury | Sep 14, 2022
Management Tracks
AZ and Novartis veteran Tommasi to lead R&D at Dunad
Plus new CSOs at Atomwise and Sotio, and updates from Nine Square, Fabric and Biolojic Design
BioCentury | May 26, 2022
Regulation
May 25 Quick Takes: Verrica shares halved after third FDA setback
Plus Chinook raises $105M through sale of 6.4 million shares, and updates from Angle, Pleno, Ellipses and more
BioCentury | Mar 1, 2022
Management Tracks
Jones leaving BMS to become CMO of Cullinan
Plus Singleton to join Bioventus as CFO, and updates from Noema, Lycia, Avidity and more
BioCentury | Sep 17, 2021
Translation in Brief
Entasis’ CARB-X-backed non-beta lactam antibiotic; plus Takeda, Amyndas and more
BioCentury’s roundup of translational news
BioCentury | Jul 14, 2021
Management Tracks
BeiGene’s Liang joins Tessera as president, CFO; plus Vera, Entasis, Iterion and Anticancer
Howard Liang joined gene writing company Tessera Therapeutics Inc. as president and CFO. Liang was most recently CFO and chief strategy officer at BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), leading the
BioCentury | Jan 18, 2020
Finance
Novo seeks to REPAIR funding in antibiotics companies
The REPAIR Impact Fund is building a reserve to support portfolio companies through Phase II trials
BioCentury | Jan 18, 2020
Finance
Novo seeks to REPAIR funding in antibiotics companies
The REPAIR Impact Fund is building a reserve to support portfolio companies through Phase II trials
Items per page:
1 - 10 of 43